<DOC>
	<DOC>NCT00000328</DOC>
	<brief_summary>The purpose of this study is to compare the clinical efficacy of the buprenorphine/naloxone combination tablet to methadone for opioid maintenance treatment.</brief_summary>
	<brief_title>Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment III) - 3</brief_title>
	<detailed_description>S/A brief "Summary for the Public"</detailed_description>
	<mesh_term>Opioid-Related Disorders</mesh_term>
	<mesh_term>Heroin Dependence</mesh_term>
	<mesh_term>Analgesics, Opioid</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<mesh_term>Buprenorphine, Naloxone Drug Combination</mesh_term>
	<mesh_term>Naloxone</mesh_term>
	<criteria>Individuals must be at least 18 years of age, currently opioid dependent and meet FDA criteria for narcotic maintenance treatment. Comorbid substance abuse or dependence disorders may also be present. Individuals must be healthy despite drug dependency. Individuals with evidence of an active Diagnostic and Statistical Manual of Mental Disorders (DSMIV) Axis I psychiatric disorder (e.g. psychosis, manicdepressive illness, organic psychiatric disorders), significant medical illness (e.g. liver or cardiovascular disease) or pregnant female subjects are excluded from study participation.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>drug dependence</keyword>
</DOC>